全球癌症治疗市场 – 2029 年行业趋势及预测

Customize Your Report Customize Your Report 立即购买 立即购买 免费样本报告 免费样本报告
Home Pharmaceutical Global Cancer Treatment Market
请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

全球癌症治疗市场 – 2029 年行业趋势及预测

  • Pharmaceutical
  • Published Report
  • Jan 2022
  • Global
  • 350 页面
  • 桌子數： 749
  • 图号： 41
立即购买 立即购买

Global Cancer Treatment Market

市场规模（十亿美元）

CAGR :  % Diagram

Diagram Forecast Period
 2022 –2029
Diagram Market Size (Base Year)
 USD 215,900.00 Million
Diagram Market Size (Forecast Year)
 USD 524,921.84 Million
Diagram CAGR
 %
Diagram Major Markets Players
  • Bristol Myers Squibb Company
  • F. Hoffman La Roche Ltd
  • Clegen
  • AbbVie
  • Pfizer

>全球癌症治疗市场，按癌症类型（乳腺癌、肝转移性结直肠癌、肺癌、前列腺癌、卵巢癌、头颈癌、胰腺癌、胶质母细胞瘤、肾细胞癌、间变性甲状腺癌、肉瘤等）、治疗方法（药物、靶向治疗、放射治疗、手术等）、给药途径（注射、口服等）、最终用户（医院、专科诊所）、国家（美国、加拿大、德国、法国、英国、意大利、西班牙、俄罗斯、土耳其、比利时、匈牙利、荷兰、瑞士、立陶宛、奥地利、挪威、爱尔兰、波兰、欧洲其他地区、澳大利亚）划分 - 行业趋势和预测（到 2029 年）

癌症治疗市场

市场分析与洞察：全球癌症治疗市场

全球癌症治疗市场预计将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2022 年至 2029 年的预测期内，市场复合年增长率为 12.1%，预计将从 2021 年的 2159 亿美元增至 2029 年的 5249.2184 亿美元。癌症的高发病率和为其有效应用而不断增加的研发活动可能是预测期内推动市场需求的主要驱动力。

癌症是一种疾病，其中某些身体细胞不受控制地生长，最终扩散到身体的其他部位。癌性肿瘤扩散到附近的组织，并可能在体内远处形成新的肿瘤。这个过程称为转移。癌性肿瘤也称为恶性肿瘤。良性肿瘤不会侵入附近的组织，当切除时，良性肿瘤通常不会复发，而癌性肿瘤有时会复发。

癌症有一百多种。一些始于特定细胞类型的癌症包括癌、肉瘤、白血病、淋巴瘤和多发性骨髓瘤等。根据癌症类型，有许多类型的癌症治疗方法。癌症治疗包括癌症治疗的生物标志物检测、化疗、激素疗法、热疗、免疫疗法、光动力疗法、放射疗法、手术、干细胞移植和靶向疗法。

根据 GLOBOCAN 的数据，2020 年全球新增癌症病例 19,292,789 例。乳腺癌病例最多。因此，癌症的高发病率、政府为提高对癌症的认识和早期发现而采取的举措以及正在进行的临床试验预计将推动市场的增长。

癌症的高发性、老年癌症的增多以及先进的癌症靶向疗法的出现有望成为市场增长的驱动力。然而，治疗的高成本和副作用可能会抑制市场的增长。产品批准的增加有望成为市场增长的机会。然而，缺乏早期疾病检测可能会对市场的增长构成挑战。

全球癌症治疗市场报告提供了市场份额、新发展和国内和本地市场参与者的影响的详细信息，分析了新兴收入来源、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况，请联系我们获取分析师简报。我们的团队将帮助您创建收入影响解决方案，以实现您的预​​期目标。

癌症治疗市场

全球癌症治疗市场范围和市场规模

全球癌症治疗市场根据癌症类型、治疗、给药途径和最终用户分为四个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。

  • 根据癌症类型，全球癌症治疗市场细分为乳腺癌、肝转移性结直肠癌、肺癌、前列腺癌、卵巢癌、头颈癌、胰腺癌、胶质母细胞瘤、肾细胞癌、未分化甲状腺癌和肉瘤。2022 年，预计乳腺癌领域将占据市场主导地位，因为政府发起的倡议和政府宣传活动越来越多，以提高人们对乳腺癌的认识并促进乳腺癌的早期发现和治疗。
  • 根据治疗方法，全球癌症治疗市场分为药物治疗、靶向治疗、放射治疗、手术和其他治疗。2022 年，由于新药上市数量增加、FDA 对各类药物的批准数量增加以及产品线强劲，药物治疗预计将占据市场主导地位。
  • 根据给药途径，全球癌症治疗市场分为注射剂、口服剂和其他剂型。预计到 2022 年，注射剂将占据市场主导地位，因为它是最相关的给药方式。
  • 根据最终用户，全球癌症治疗市场分为医院和专科诊所。预计到 2022 年，医院将占据市场主导地位，因为发达国家和发展中国家的富裕医院对晚期癌症治疗的需求很高，因为患者对医疗保健的关注度不断上升。

癌症治疗市场

全球癌症治疗市场国家级分析

对全球癌症治疗市场进行了分析，并按地理位置、癌症类型、治疗、给药途径和最终用户提供了市场规模信息。

全球癌症治疗市场报告涵盖的国家包括美国、加拿大、德国、法国、英国、意大利、西班牙、俄罗斯、土耳其、比利时、匈牙利、荷兰、瑞士、立陶宛、奥地利、挪威、爱尔兰、波兰、欧洲其他地区和澳大利亚。

美国预计将在北美地区主导全球癌症治疗，因为美国是最大的消费市场，GDP 较高，癌症患者数量不断增加，且市场参与者众多。德国预计将在欧洲地区主导癌症治疗市场，因为德国存在尚未开发的机会、对癌症治疗的需求不断增加，以及德国老年人口不断增长。乳腺癌领域预计将在市场上占据主导地位，因为政府发起的倡议和政府宣传活动越来越多，以提高人们对乳腺癌的认识，并实现早期发现和治疗。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、销售渠道的影响。 

技术发展和公私融资正在为全球癌症治疗市场  创造机遇

全球癌症治疗市场还为您提供每个国家/地区特定行业增长的详细市场分析，包括伤口清创设备销售、市场发展的影响、监管环境的变化及其对癌症治疗市场的支持。数据涵盖 2011 年至 2020 年的历史时期。

竞争格局和全球癌症治疗份额分析

全球癌症治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对全球癌症治疗市场的关注有关。

全球癌症治疗市场的一些主要公司包括百时美施贵宝公司、霍夫曼罗氏有限公司、Clegen、艾伯维公司、辉瑞公司和诺华公司等。

市场参与者的战略举措和癌症治疗的新技术进步正在弥合各种治疗之间的差距。

例如，

  • 2020 年 12 月，罗氏制药宣布其药物 Gavreto 已获得美国食品药品监督管理局批准，用于治疗需要全身治疗的晚期或转移性转染突变型髓样甲状腺癌的 12 岁以上儿童和成人患者。此举有助于该公司扩大其产品组合。

市场参与者的合作、合资和其他策略正在增强公司在癌症治疗市场的市场，这也有利于该组织改善其在全球癌症治疗市场的供应。

 

 

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

Sample Image Click on image to enlarge
  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 CANCER TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 VENDOR SHARE ANALYSIS

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTERS FIVE FORCES

5 EPIDEMOLOGY

6 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: REGULATORY SCENARIO

6.1 TIMELINE TO APPROVE A DRUG

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 GROWING CANCER BURDEN WORLDWIDE

7.1.2 GROWING GERIATRIC POPULATION

7.1.3 AVAILABILITY OF DIFFERENT TYPES OF TARGETED THERAPIES

7.1.4 RISING NUMBER OF FDA APPROVAL

7.1.5 GROWING R&D ACTIVITIES

7.2 RESTRAINTS

7.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER TREATMENT DRUGS

7.2.2 HIGH COST OF CANCER TREATMENT

7.2.3 LACK OF EARLY DETECTION

7.3 OPPORTUNITIES

7.3.1 STRATEGIC DEVELOPMENT AMONG MAJOR PLAYERS

7.3.2 INCREASING INITIATIVES BY GOVERNMENT AND OTHER HEALTHCARE ORGANIZATIONS

7.3.3 RISING EXPENDITURE ON CANCER TREATMENT

7.4 CHALLENGES

7.4.1 PATENT EXPIRY OF DRUGS

8 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY CANCER TYPE

8.1 OVERVIEW

8.2 BREAST CANCER

8.3 COLORECTAL CANCER WITH LIVER METASTASES

8.4 LUNG CARCINOMA

8.5 PROSTATE CANCER

8.6 OVARIAN CANCER

8.7 HEAD-AND-NECK CANCER

8.8 PANCREATIC CANCER

8.9 GLIOBLASTOMA

8.1 RENAL CELL CARCINOMA

8.11 ANAPLASTIC THYROID CARCINOMA

8.12 SARCOMA

9 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY TREATMENT

9.1 OVERVIEW

9.2 MEDICATION

9.2.1 BY DRUG TYPE

9.2.1.1 LUNG CARCINOMA

9.2.1.1.1 NIVOLUMAB (OPDIVO)

9.2.1.1.2 BEVACIZUMAB (AVASTIN)

9.2.1.1.3 CRIZOTINIB (XALKORI)

9.2.1.1.4 ERLOTINIB (TARCEVA)

9.2.1.1.5 GEFITINIB (IRESSA)

9.2.1.1.6 AFATINIB DIMALEATE (GILOTRIF)

9.2.1.1.7 CERITINIB (LDK378/ZYKADIA)

9.2.1.1.8 RAMUCIRUMAB (CYRAMZA)

9.2.1.1.9 OTHERS

9.2.1.2 COLORECTAL CANCER WITH LIVER METASTASES

9.2.1.2.1 NIVOLUMAB (OPDIVO)

9.2.1.2.2 CETUXIMAB (ERBITUX)

9.2.1.2.3 PANITUMUMAB (VECTIBIX)

9.2.1.2.4 BEVACIZUMAB (AVASTIN)

9.2.1.2.5 ZIV-AFLIBERCEPT (ZALTRAP)

9.2.1.2.6 REGORAFENIB (STIVARGA)

9.2.1.2.7 RAMUCIRUMAB (CYRAMZA)

9.2.1.2.8 IPILIMUMAB (YERVOY)

9.2.1.2.9 ENCORAFENIB (BRAFTOVI)

9.2.1.2.10 PEMBROLIZUMAB (KEYTRUDA)

9.2.1.2.11 OTHERS

9.2.1.3 OVARIAN CANCER

9.2.1.3.1 BEVACIZUMAB (AVASTIN)

9.2.1.3.2 OLAPARIB (LYNPARZA)

9.2.1.3.3 RUCAPARIB CAMSYLATE (RUBRACA)

9.2.1.3.4 NIRAPARIB TOSYLATE MONOHYDRATE (ZEJULA)

9.2.1.3.5 OTHERS

9.2.1.4 HEAD-AND-NECK CANCER

9.2.1.4.1 CETUXIMAB (ERBITUX)

9.2.1.4.2 PEMBROLIZUMAB (KEYTRUDA)

9.2.1.4.3 NIVOLUMAB (OPDIVO)

9.2.1.4.4 OTHERS

9.2.1.5 RENAL CELL CARCINOMA

9.2.1.5.1 NIVOLUMAB (OPDIVO)

9.2.1.5.2 BEVACIZUMAB (AVASTIN)

9.2.1.5.3 SORAFENIB (NEXAVAR)

9.2.1.5.4 SUNITINIB (SUTENT)

9.2.1.5.5 PAZOPANIB (VOTRIENT)

9.2.1.5.6 TEMSIROLIMUS (TORISEL)

9.2.1.5.7 EVEROLIMUS (AFINITOR)

9.2.1.5.8 AXITINIB (INLYTA)

9.2.1.5.9 CABOZANTINIB (CABOMETYX)

9.2.1.5.10 OTHERS

9.2.1.6 ANAPLASTIC THYROID CARCINOMA

9.2.1.6.1 CABOZANTINIB (COMETRIQ)

9.2.1.6.2 VANDETANIB (CAPRELSA)

9.2.1.6.3 SORAFENIB (NEXAVAR)

9.2.1.6.4 LENVATINIB MESYLATE (LENVIMA)

9.2.1.6.5 TRAMETINIB (MEKINIST)

9.2.1.6.6 DABRAFENIB (TAFINLAR)

9.2.1.6.7 SELPERCATINIB (RETEVMO)

9.2.1.6.8 PRALSETINIB (GAVRETO)

9.2.1.6.9 OTHERS

9.2.1.7 BREAST CANCER

9.2.1.7.1 EVEROLIMUS (AFINITOR)

9.2.1.7.2 TAMOXIFEN (NOLVADEX)

9.2.1.7.3 TRASTUZUMAB (HERCEPTIN)

9.2.1.7.4 FULVESTRANT (FASLODEX)

9.2.1.7.5 ANASTROZOLE (ARIMIDEX)

9.2.1.7.6 EXEMESTANE (AROMASIN)

9.2.1.7.7 LETROZOLE (FEMARA)

9.2.1.7.8 PERTUZUMAB (PERJETA)

9.2.1.7.9 PALBOCICLIB (IBRANCE)

9.2.1.7.10 RIBOCICLIB (KISQALI)

9.2.1.7.11 TOSYLATE (TALZENNA)

9.2.1.7.12 PEMBROLIZUMAB (KEYTRUDA)

9.2.1.7.13 MARGETUXIMAB-CMKB (MARGENZA)

9.2.1.7.14 OTHERS

9.2.1.8 PROSTATE CANCER

9.2.1.8.1 CABAZITAXEL (JEVTANA)

9.2.1.8.2 ENZALUTAMIDE (XTANDI)

9.2.1.8.3 ABIRATERONE ACETATE (ZYTIGA)

9.2.1.8.4 RADIUM 223 DICHLORIDE (XOFIGO)

9.2.1.8.5 APALUTAMIDE (ERLEADA)

9.2.1.8.6 DAROLUTAMIDE (NUBEQA)

9.2.1.8.7 RUCAPARIB CAMSYLATE (RUBRACA)

9.2.1.8.8 OLAPARIB (LYNPARZA)

9.2.1.8.9 OTHERS

9.2.1.9 PANCREATIC CANCER

9.2.1.9.1 ERLOTINIB (TARCEVA)

9.2.1.9.2 EVEROLIMUS (AFINITOR)

9.2.1.9.3 SUNITINIB (SUTENT)

9.2.1.9.4 OLAPARIB (LYNPARZA)

9.2.1.9.5 BELZUTIFAN (WELIREG)

9.2.1.9.6 OTHERS

9.2.1.10 GLIOBLASTOMA

9.2.1.10.1 BEVACIZUMAB (AVASTIN)

9.2.1.10.2 EVEROLIMUS (AFINITOR)

9.2.1.10.3 BELZUTIFAN (WELIREG)

9.2.1.10.4 OTHERS

9.2.1.11 SARCOMA

9.2.1.11.1 COSMEGEN (DACTINOMYCIN)

9.2.1.11.2 DACTINOMYCIN

9.2.1.11.3 DOXORUBICIN HYDROCHLORIDE

9.2.1.11.4 ERIBULIN MESYLATE

9.2.1.11.5 GLEEVEC (IMATINIB MESYLATE)

9.2.1.11.6 HALAVEN (ERIBULIN MESYLATE)

9.2.1.11.7 IMATINIB MESYLATE

9.2.1.11.8 PAZOPANIB HYDROCHLORIDE

9.2.1.11.9 TAZEMETOSTAT HYDROBROMIDE

9.2.1.11.10 TAZVERIK (TAZEMETOSTAT HYDROBROMIDE)

9.2.1.11.11 TRABECTEDIN

9.2.1.11.12 VOTRIENT (PAZOPANIB HYDROCHLORIDE)

9.2.1.11.13 YONDELIS (TRABECTEDIN)

9.2.1.11.14 OTHERS

9.2.2 BY VACCINES

9.2.2.1 CERVARIX

9.2.2.2 GARDASIL

9.2.2.3 GARDASIL-9

9.2.2.4 HEPATITIS B (HBV) VACCINE (HEPLISAV-B)

9.2.2.5 SIPULEUCEL-T (PROVENGE)

9.2.2.6 OTHERS

9.3 RADIOTHERAPY

9.3.1 EXTERNAL BEAM RADIATION THERAPY

9.3.1.1 THREE -DIMENSIONAL CONFROMAL RADIATION THERAPY (3-D CRT)

9.3.1.2 PROTON THERAPY

9.3.1.3 INTENSITY-MODULATED RADIATION THERAPY (IMRT)

9.3.1.4 IMAGE-GUIDED RADIATION THERAPY (IGRT)

9.3.1.5 TOMOTHERAPY

9.3.1.6 STEREOTACTIC RADIOSURGERY

9.3.1.7 STEREOTACTIC BODY RADIATION THERAPY (SRT)

9.3.1.8 INTRAOPERATIVE RADIATION THERAPY

9.3.1.9 OTHERS

9.3.2 INTERNAL RADIATION THERAPY (BRACHYTHERAPY)

9.3.2.1 LOW-DOSE-RATE (LDR) BRACHYTHERAPY

9.3.2.2 HIGH-DOSE-RATE (HDR) BRACHYTHERAPY

9.3.3 SYSTEMIC RADIATION THERAPY

9.3.3.1 PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)

9.3.3.2 OTHERS

9.4 SURGERY

9.4.1 PAROTIDECTOMY

9.4.2 ENDOSCOPIC SURGERY

9.4.3 NECK DISSECTION

9.4.4 RECONSTRUCTIVE SURGERY

9.4.5 OTHERS

9.5 TARGETED THERAPIES

9.5.1 SMALL MOLECULES

9.5.1.1 TYROSINE & SERINE/THREONINE KINASES

9.5.1.1.1 IMATINIB (GLEEVEC)

9.5.1.1.2 GEFITINIB (IRESSA)

9.5.1.1.3 ERLOTINIB (TARCEVA)

9.5.1.1.4 SUNITINIB (SUTENT)

9.5.1.1.5 PERIFOSINE

9.5.1.1.6 OTHERS

9.5.1.2 PROTEOSOMES

9.5.1.2.1 BORTEZOMIB (VELCADE)

9.5.1.2.2 CARFILZOMIB (KYPROLIS)

9.5.1.2.3 MARIZOMIB

9.5.1.3 MMPS AND HSPS

9.5.1.3.1 BATIMASTAT

9.5.1.3.2 NEOVASTAT

9.5.1.3.3 PRINOMASTAT

9.5.1.3.4 REBIMASTAT

9.5.1.3.5 GANETESPIB

9.5.1.3.6 OTHERS

9.5.1.4 APOPTOSIS

9.5.1.4.1 OBATOCLAX

9.5.1.4.2 NAVITOCLAX

9.5.1.4.3 OTHERS

9.5.2 IMMUNOTHERAPY

9.5.2.1 IMMUNE CHECKPOINT INHIBITORS

9.5.2.2 T-CELL TRANSFER THERAPY

9.5.2.2.1 TIL THERAPY

9.5.2.2.2 CAR T-CELL THERAPY

9.5.2.2.3 BY PRODUCT

9.5.2.2.3.1 TISAGENLECLEUCEL (KYMRIAH)

9.5.2.2.3.2 AXICABTAGENE CILOLEUCEL (YESCARTA)

9.5.2.2.3.3 BREXUCABTAGENE AUTOLEUCEL (TECARTUS)

9.5.2.2.3.4 OTHERS

9.5.2.2.4 BY TECHNOLOGY

9.5.2.2.4.1 AUTOLOGOUS

9.5.2.2.4.2 ALLOGENEIC

9.5.2.3 MONOCLONAL ANTIBODIES

9.5.2.3.1 RITUXIMAB

9.5.2.3.2 BLINATUMOMAB (BLINCYTO)

9.5.2.3.3 OTHERS

9.5.2.4 IMMUNE SYSTEM MODULATORS

9.5.2.4.1 CYTOKINES

9.5.2.4.2 INTERFERONS (INFS)

9.5.2.4.3 INTERLEUKINS (ILS)

9.5.2.4.4 HEMATOPOIETIC GROWTH FACTORS

9.5.2.4.5 BCG

9.5.2.4.6 IMMUNOMODULATORY DRUGS/BIOLOGICAL RESPONSE MODIFIERS

9.5.2.4.7 THALIDOMIDE (THALOMID)

9.5.2.4.8 LENALIDOMIDE (REVLIMID)

9.5.2.4.9 POMALIDOMIDE (POMALYST)

9.5.2.4.10 IMIQUIMOD (ALDARA, ZYCLARA)

9.5.2.4.11 OTHERS

9.5.2.5 TREATMENT VACCINES

9.5.2.6 OTHERS

9.5.3 HORMONAL THERAPY

9.5.3.1 SIGNAL TRANSDUCTION INHIBITORS

9.5.3.2 GENE EXPRESSION MODULATORS

9.5.3.3 APOPTOSIS INDUCERS

9.5.3.4 ANGIOGENESIS INHIBITORS

9.5.3.5 GENE THERAPY

9.5.3.6 OTHERS

9.6 OTHERS

10 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 INJECTABLE

10.3 ORAL

10.4 OTHERS

11 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 SPECIALTY CLINICS

12 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY REGION

12.1 OVERVIEW

12.2 EUROPE

12.2.1 GERMANY

12.2.2 FRANCE

12.2.3 U.K.

12.2.4 ITALY

12.2.5 SPAIN

12.2.6 NETHERLANDS

12.2.7 DENMARK

12.2.8 SWITZERLAND

12.2.9 SWEDEN

12.2.10 AUSTRIA

12.2.11 NORWAY

12.2.12 HUNGARY

12.2.13 GREECE

12.2.14 IRELAND

12.2.15 POLAND

12.2.16 REST OF EUROPE

12.3 AUSTRALIA

12.4 U.S.

12.5 CANADA

13 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: GLOBAL

13.2 COMPANY SHARE ANALYSIS: EUROPE

14 QUESTIONNAIRE

15 RELATED REPORTS

表格列表

TABLE 1 DIFFERENCES IN APPROVAL TIMES BETWEEN EMEA AND FDA FOR SELECTED TARGETED THERAPIES SINCE 2001

TABLE 2 NEW CANCER CASES, AGES 85+ IN THE U.S.

TABLE 3 DEATH CAUSES DUE TO CANCER, AGES 85+ IN THE U.S.

TABLE 4 HERE ARE SOME STATISTICS RELATED TO THE TREATMENT COST:

TABLE 5 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 6 GLOBAL BREAST CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 GLOBAL COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 GLOBAL LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 GLOBAL PROSTATE CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 GLOBAL OVARIAN CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 GLOBAL HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 GLOBAL PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 GLOBAL GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 GLOBAL RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 GLOBAL ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 GLOBAL SARCOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 18 GLOBAL MEDICATION IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 GLOBAL MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 20 GLOBAL BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 21 GLOBAL LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 22 GLOBAL LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 23 GLOBAL OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 24 GLOBAL HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 25 GLOBAL RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 26 GLOBAL ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 27 GLOBAL BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 28 GLOBAL PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 29 GLOBAL PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 30 GLOBAL GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 31 GLOBAL SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 32 GLOBAL BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 33 GLOBAL RADIOTHERAPY IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 GLOBAL RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 35 GLOBAL EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 36 GLOBAL INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 37 GLOBAL SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 38 GLOBAL SURGERY IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 GLOBAL SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 40 GLOBAL TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 GLOBAL TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 42 GLOBAL SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 43 GLOBAL TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 44 GLOBAL PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 45 GLOBAL MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 46 GLOBAL APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 47 GLOBAL IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 48 GLOBAL T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 49 GLOBAL BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 50 GLOBAL BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 51 GLOBAL MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 52 GLOBAL IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 53 GLOBAL HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 54 GLOBAL OTHERS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 55 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 56 GLOBAL INJECTABLE IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 57 GLOBAL ORAL IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 58 GLOBAL OTHERS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 59 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 60 GLOBAL HOSPITALS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 61 GLOBAL SPECIALTY CLINICS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 62 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 63 EUROPE CANCER TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 64 EUROPE CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 65 EUROPE CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 66 EUROPE MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 67 EUROPE BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 68 EUROPE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 69 EUROPE COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 70 EUROPE OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 71 EUROPE HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 72 EUROPE RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 73 EUROPE ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 74 EUROPE BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 75 EUROPE PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 76 EUROPE PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 77 EUROPE GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 78 EUROPE SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 79 EUROPE BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 80 EUROPE RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 81 EUROPE EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 82 EUROPE INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 83 EUROPE SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 84 EUROPE SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 85 EUROPE TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 86 EUROPE SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 87 EUROPE TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 88 EUROPE PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 89 EUROPE MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 90 EUROPE APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 91 EUROPE IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 92 EUROPE T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 93 EUROPE BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 94 EUROPE BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 95 EUROPE MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 96 EUROPE IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 97 EUROPE HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 98 EUROPE CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 99 EUROPE CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 100 GERMANY CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 101 GERMANY CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 102 GERMANY MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 103 GERMANY BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 104 GERMANY LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 105 GERMANY COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 106 GERMANY OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 107 GERMANY HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 108 GERMANY RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 109 GERMANY ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 110 GERMANY BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 111 GERMANY PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 112 GERMANY PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 113 GERMANY GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 114 GERMANY SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 115 GERMANY BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 116 GERMANY RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 117 GERMANY EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 118 GERMANY INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 119 GERMANY SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 120 GERMANY SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 121 GERMANY TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 122 GERMANY SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 123 GERMANY TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 124 GERMANY PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 125 GERMANY MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 126 GERMANY APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 127 GERMANY IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 128 GERMANY T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 129 GERMANY BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 130 GERMANY BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 131 GERMANY MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 132 GERMANY IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 133 GERMANY HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 134 GERMANY CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 135 GERMANY CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 136 FRANCE CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 137 FRANCE CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 138 FRANCE MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 139 FRANCE BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 140 FRANCE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 141 FRANCE COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 142 FRANCE OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 143 FRANCE HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 144 FRANCE RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 145 FRANCE ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 146 FRANCE BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 147 FRANCE PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 148 FRANCE PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 149 FRANCE GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 150 FRANCE SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 151 FRANCE BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 152 FRANCE RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 153 FRANCE EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 154 FRANCE INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 155 FRANCE SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 156 FRANCE SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 157 FRANCE TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 158 FRANCE SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 159 FRANCE TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 160 FRANCE PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 161 FRANCE MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 162 FRANCE APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 163 FRANCE IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 164 FRANCE T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 165 FRANCE BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 166 FRANCE BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 167 FRANCE MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 168 FRANCE IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 169 FRANCE HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 170 FRANCE CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 171 FRANCE CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 172 U.K. CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 173 U.K. CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 174 U.K. MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 175 U.K. BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 176 U.K. LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 177 U.K. COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 178 U.K. OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 179 U.K. HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 180 U.K. RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 181 U.K. ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 182 U.K. BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 183 U.K. PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 184 U.K. PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 185 U.K. GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 186 U.K. SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 187 U.K. BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 188 U.K. RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 189 U.K. EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 190 U.K. INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 191 U.K. SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 192 U.K. SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 193 U.K. TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 194 U.K. SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 195 U.K. TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 196 U.K. PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 197 U.K. MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 198 U.K. APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 199 U.K. IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 200 U.K. T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 201 U.K. BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 202 U.K. BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 203 U.K. MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 204 U.K. IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 205 U.K. HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 206 U.K. CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 207 U.K. CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 208 ITALY CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 209 ITALY CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 210 ITALY MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 211 ITALY BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 212 ITALY LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 213 ITALY COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 214 ITALY OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 215 ITALY HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 216 ITALY RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 217 ITALY ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 218 ITALY BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 219 ITALY PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 220 ITALY PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 221 ITALY GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 222 ITALY SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 223 ITALY BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 224 ITALY RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 225 ITALY EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 226 ITALY INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 227 ITALY SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 228 ITALY SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 229 ITALY TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 230 ITALY SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 231 ITALY TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 232 ITALY PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 233 ITALY MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 234 ITALY APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 235 ITALY IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 236 ITALY T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 237 ITALY BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 238 ITALY BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 239 ITALY MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 240 ITALY IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 241 ITALY HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 242 ITALY CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 243 ITALY CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 244 SPAIN CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 245 SPAIN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 246 SPAIN MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 247 SPAIN BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 248 SPAIN LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 249 SPAIN COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 250 SPAIN OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 251 SPAIN HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 252 SPAIN RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 253 SPAIN ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 254 SPAIN BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 255 SPAIN PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 256 SPAIN PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 257 SPAIN GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 258 SPAIN SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 259 SPAIN BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 260 SPAIN RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 261 SPAIN EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 262 SPAIN INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 263 SPAIN SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 264 SPAIN SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 265 SPAIN TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 266 SPAIN SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 267 SPAIN TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 268 SPAIN PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 269 SPAIN MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 270 SPAIN APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 271 SPAIN IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 272 SPAIN T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 273 SPAIN BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 274 SPAIN BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 275 SPAIN MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 276 SPAIN IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 277 SPAIN HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 278 SPAIN CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 279 SPAIN CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 280 NETHERLANDS CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 281 NETHERLANDS CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 282 NETHERLANDS MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 283 NETHERLANDS BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 284 NETHERLANDS LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 285 NETHERLANDS COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 286 NETHERLANDS OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 287 NETHERLANDS HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 288 NETHERLANDS RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 289 NETHERLANDS ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 290 NETHERLANDS BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 291 NETHERLANDS PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 292 NETHERLANDS PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 293 NETHERLANDS GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 294 NETHERLANDS SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 295 NETHERLANDS BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 296 NETHERLANDS RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 297 NETHERLANDS EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 298 NETHERLANDS INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 299 NETHERLANDS SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 300 NETHERLANDS SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 301 NETHERLANDS TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 302 NETHERLANDS SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 303 NETHERLANDS TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 304 NETHERLANDS PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 305 NETHERLANDS MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 306 NETHERLANDS APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 307 NETHERLANDS IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 308 NETHERLANDS T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 309 NETHERLANDS BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 310 NETHERLANDS BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 311 NETHERLANDS MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 312 NETHERLANDS IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 313 NETHERLANDS HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 314 NETHERLANDS CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 315 NETHERLANDS CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 316 DENMARK CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 317 DENMARK CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 318 DENMARK MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 319 DENMARK BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 320 DENMARK LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 321 DENMARK COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 322 DENMARK OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 323 DENMARK HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 324 DENMARK RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 325 DENMARK ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 326 DENMARK BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 327 DENMARK PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 328 DENMARK PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 329 DENMARK GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 330 DENMARK SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 331 DENMARK BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 332 DENMARK RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 333 DENMARK EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 334 DENMARK INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 335 DENMARK SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 336 DENMARK SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 337 DENMARK TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 338 DENMARK SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 339 DENMARK TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 340 DENMARK PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 341 DENMARK MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 342 DENMARK APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 343 DENMARK IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 344 DENMARK T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 345 DENMARK BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 346 DENMARK BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 347 DENMARK MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 348 DENMARK IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 349 DENMARK HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 350 DENMARK CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 351 DENMARK CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 352 SWITZERLAND CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 353 SWITZERLAND CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 354 SWITZERLAND MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 355 SWITZERLAND BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 356 SWITZERLAND LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 357 SWITZERLAND COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 358 SWITZERLAND OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 359 SWITZERLAND HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 360 SWITZERLAND RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 361 SWITZERLAND ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 362 SWITZERLAND BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 363 SWITZERLAND PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 364 SWITZERLAND PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 365 SWITZERLAND GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 366 SWITZERLAND SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 367 SWITZERLAND BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 368 SWITZERLAND RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 369 SWITZERLAND EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 370 SWITZERLAND INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 371 SWITZERLAND SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 372 SWITZERLAND SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 373 SWITZERLAND TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 374 SWITZERLAND SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 375 SWITZERLAND TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 376 SWITZERLAND PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 377 SWITZERLAND MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 378 SWITZERLAND APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 379 SWITZERLAND IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 380 SWITZERLAND T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 381 SWITZERLAND BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 382 SWITZERLAND BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 383 SWITZERLAND MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 384 SWITZERLAND IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 385 SWITZERLAND HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 386 SWITZERLAND CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 387 SWITZERLAND CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 388 SWEDEN CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 389 SWEDEN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 390 SWEDEN MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 391 SWEDEN BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 392 SWEDEN LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 393 SWEDEN COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 394 SWEDEN OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 395 SWEDEN HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 396 SWEDEN RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 397 SWEDEN ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 398 SWEDEN BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 399 SWEDEN PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 400 SWEDEN PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 401 SWEDEN GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 402 SWEDEN SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 403 SWEDEN BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 404 SWEDEN RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 405 SWEDEN EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 406 SWEDEN INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 407 SWEDEN SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 408 SWEDEN SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 409 SWEDEN TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 410 SWEDEN SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 411 SWEDEN TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 412 SWEDEN PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 413 SWEDEN MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 414 SWEDEN APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 415 SWEDEN IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 416 SWEDEN T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 417 SWEDEN BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 418 SWEDEN BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 419 SWEDEN MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 420 SWEDEN IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 421 SWEDEN HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 422 SWEDEN CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 423 SWEDEN CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 424 AUSTRIA CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 425 AUSTRIA CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 426 AUSTRIA MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 427 AUSTRIA BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 428 AUSTRIA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 429 AUSTRIA COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 430 AUSTRIA OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 431 AUSTRIA HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 432 AUSTRIA RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 433 AUSTRIA ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 434 AUSTRIA BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 435 AUSTRIA PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 436 AUSTRIA PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 437 AUSTRIA GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 438 AUSTRIA SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 439 AUSTRIA BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 440 AUSTRIA RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 441 AUSTRIA EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 442 AUSTRIA INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 444 AUSTRIA SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 445 AUSTRIA SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 446 AUSTRIA TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 447 AUSTRIA SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 448 AUSTRIA TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 449 AUSTRIA PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 450 AUSTRIA MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 451 AUSTRIA APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 452 AUSTRIA IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 453 AUSTRIA T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 454 AUSTRIA BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 455 AUSTRIA BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 456 AUSTRIA MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 457 AUSTRIA IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 458 AUSTRIA HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 459 AUSTRIA CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 460 AUSTRIA CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 461 NORWAY CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 462 NORWAY CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 463 NORWAY MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 464 NORWAY BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 465 NORWAY LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 466 NORWAY COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 467 NORWAY OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 468 NORWAY HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 469 NORWAY RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 470 NORWAY ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 471 NORWAY BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 472 NORWAY PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 473 NORWAY PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 474 NORWAY GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 475 NORWAY SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 476 NORWAY BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 477 NORWAY RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 478 NORWAY EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 479 NORWAY INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 480 NORWAY SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 481 NORWAY SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 482 NORWAY TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 483 NORWAY SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 484 NORWAY TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 485 NORWAY PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 486 NORWAY MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 487 NORWAY APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 488 NORWAY IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 489 NORWAY T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 490 NORWAY BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 491 NORWAY BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 492 NORWAY MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 493 NORWAY IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 494 NORWAY HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 495 NORWAY CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 496 NORWAY CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 497 HUNGARY CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 498 HUNGARY CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 499 HUNGARY MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 500 HUNGARY BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 501 HUNGARY LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 502 HUNGARY COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 503 HUNGARY OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 504 HUNGARY HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 505 HUNGARY RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 506 HUNGARY ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 507 HUNGARY BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 508 HUNGARY PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 509 HUNGARY PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 510 HUNGARY GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 511 HUNGARY SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 512 HUNGARY BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 513 HUNGARY RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 514 HUNGARY EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 515 HUNGARY INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 516 HUNGARY SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 517 HUNGARY SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 518 HUNGARY TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 519 HUNGARY SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 520 HUNGARY TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 521 HUNGARY PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 522 HUNGARY MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 523 HUNGARY APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 524 HUNGARY IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 525 HUNGARY T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 526 HUNGARY BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 527 HUNGARY BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 528 HUNGARY MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 529 HUNGARY IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 530 HUNGARY HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 531 HUNGARY CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 532 HUNGARY CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 533 GREECE CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 534 GREECE CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 535 GREECE MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 536 GREECE BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 537 GREECE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 538 GREECE COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 539 GREECE OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 540 GREECE HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 541 GREECE RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 542 GREECE ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 543 GREECE BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 544 GREECE PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 545 GREECE PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 546 GREECE GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 547 GREECE SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 548 GREECE BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 549 GREECE RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 550 GREECE EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 551 GREECE INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 552 GREECE SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 553 GREECE SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 554 GREECE TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 555 GREECE SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 556 GREECE TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 557 GREECE PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 558 GREECE MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 559 GREECE APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 560 GREECE IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 561 GREECE T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 562 GREECE BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 563 GREECE BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 564 GREECE MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 565 GREECE IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 566 GREECE HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 567 GREECE CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 568 GREECE CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 569 IRELAND CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 570 IRELAND CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 571 IRELAND MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 572 IRELAND BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 573 IRELAND LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 574 IRELAND COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 575 IRELAND OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 576 IRELAND HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 577 IRELAND RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 578 IRELAND ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 579 IRELAND BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 580 IRELAND PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 581 IRELAND PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 582 IRELAND GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 583 IRELAND SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 584 IRELAND BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 585 IRELAND RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 586 IRELAND EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 587 IRELAND INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 588 IRELAND SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 589 IRELAND SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 590 IRELAND TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 591 IRELAND SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 592 IRELAND TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 593 IRELAND PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 594 IRELAND MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 595 IRELAND APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 596 IRELAND IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 597 IRELAND T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 598 IRELAND BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 599 IRELAND BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 600 IRELAND MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 601 IRELAND IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 602 IRELAND HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 603 IRELAND CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 604 IRELAND CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 605 POLAND CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 606 POLAND CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 607 POLAND MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 608 POLAND BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 609 POLAND LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 610 POLAND COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 611 POLAND OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 612 POLAND HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 613 POLAND RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 614 POLAND ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 615 POLAND BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 616 POLAND PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 617 POLAND PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 618 POLAND GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 619 POLAND SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 620 POLAND BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 621 POLAND RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 622 POLAND EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 623 POLAND INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 624 POLAND SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 625 POLAND SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 626 POLAND TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 627 POLAND SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 628 POLAND TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 629 POLAND PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 630 POLAND MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 631 POLAND APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 632 POLAND IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 633 POLAND T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 634 POLAND BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 635 POLAND BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 636 POLAND MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 637 POLAND IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 638 POLAND HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 639 POLAND CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 640 POLAND CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 641 REST OF EUROPE CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 642 AUSTRALIA CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 643 AUSTRALIA CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 644 AUSTRALIA MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 645 AUSTRALIA BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 646 AUSTRALIA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 647 AUSTRALIA COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 648 AUSTRALIA OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 649 AUSTRALIA HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 650 AUSTRALIA RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 651 AUSTRALIA ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 652 AUSTRALIA BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 653 AUSTRALIA PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 654 AUSTRALIA PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 655 AUSTRALIA GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 656 AUSTRALIA SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 657 AUSTRALIA BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 658 AUSTRALIA RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 659 AUSTRALIA EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 660 AUSTRALIA INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 661 AUSTRALIA SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 662 AUSTRALIA SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 663 AUSTRALIA TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 664 AUSTRALIA SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 665 AUSTRALIA TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 666 AUSTRALIA PROTEASOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 667 AUSTRALIA MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 668 AUSTRALIA APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 669 AUSTRALIA IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 670 AUSTRALIA T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 671 AUSTRALIA BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 672 AUSTRALIA BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 673 AUSTRALIA MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 674 AUSTRALIA IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 675 AUSTRALIA HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 676 AUSTRALIA CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 677 AUSTRALIA CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 678 U.S. CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 679 U.S. CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 680 U.S. MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 681 U.S. BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 682 U.S. LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 683 U.S. COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 684 U.S. OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 685 U.S. HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 686 U.S. RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 687 U.S. ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 688 U.S. BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 689 U.S. PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 690 U.S. PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 691 U.S. GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 692 U.S. SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 693 U.S. BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 694 U.S. RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 695 U.S. EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 696 U.S. INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 697 U.S. SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 698 U.S. SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 699 U.S. TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 700 U.S. SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 701 U.S. TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 702 U.S. PROTEASOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 703 U.S. MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 704 U.S. APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 705 U.S. IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 706 U.S. T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 707 U.S. BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 708 U.S. BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 709 U.S. MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 710 U.S. IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 711 U.S. HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 712 U.S. CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 713 U.S. CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 714 CANADA CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 715 CANADA CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 716 CANADA MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 717 CANADA BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 718 CANADA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 719 CANADA COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 720 CANADA OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 721 CANADA HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 722 CANADA RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 723 CANADA ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 724 CANADA BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 725 CANADA PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 726 CANADA PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 727 CANADA GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 728 CANADA SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 729 CANADA BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 730 CANADA RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 731 CANADA EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 732 CANADA INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 733 CANADA SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 734 CANADA SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 735 CANADA TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 736 CANADA SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 737 CANADA TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 738 CANADA PROTEASOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 739 CANADA MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 740 CANADA APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 741 CANADA IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 742 CANADA T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 743 CANADA BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 744 CANADA BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 745 CANADA MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 746 CANADA IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 747 CANADA HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 748 CANADA CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 749 CANADA CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

图片列表

FIGURE 1 GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: SEGMENTATION

FIGURE 2 GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 8 GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: SEGMENTATION

FIGURE 9 HIGH PREVALENCE OF CANCER IS EXPECTED TO DRIVE THE GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 10 BREAST CANCER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET IN 2022 TO 2029

FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET

FIGURE 12 ESTIMATED NUMBER OF NEW CASES AND DEATHS BY VARIOUS TYPES OF CANCER WORLDWIDE, 2020

FIGURE 13 ESTIMATED NUMBER OF NEW CASES IN 2018, WORLDWIDE, BOTH SEXES, ALL AGES

FIGURE 14 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY CANCER TYPE, 2021

FIGURE 15 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY CANCER TYPE, 2020-2029 (USD MILLION)

FIGURE 16 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY CANCER TYPE, CAGR (2022-2029)

FIGURE 17 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 18 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY TREATMENT, 2021

FIGURE 19 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY TREATMENT, 2020-2029 (USD MILLION)

FIGURE 20 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY TREATMENT CAGR (2022-2029)

FIGURE 21 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY TREATMENT LIFELINE CURVE

FIGURE 22 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 23 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

FIGURE 24 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 25 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION LIFELINE CURVE

FIGURE 26 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY END USER, 2021

FIGURE 27 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 28 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY END USER, CAGR (2022-2029)

FIGURE 29 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY END USER LIFELINE CURVE

FIGURE 30 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: SNAPSHOT (2021)

FIGURE 31 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY REGION (2021)

FIGURE 32 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY REGION (2022 & 2029)

FIGURE 33 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY REGION (2021 & 2029)

FIGURE 34 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY CANCER TYPE (2022-2029)

FIGURE 35 EUROPE CANCER TREATMENT MARKET: SNAPSHOT (2021)

FIGURE 36 EUROPE CANCER TREATMENT MARKET: BY COUNTRY (2021)

FIGURE 37 EUROPE CANCER TREATMENT MARKET: BY COUNTRY (2022 & 2029)

FIGURE 38 EUROPE CANCER TREATMENT MARKET: BY COUNTRY (2021 & 2029)

FIGURE 39 EUROPE CANCER TREATMENT MARKET: BY CANCER TYPE (2022-2029)

FIGURE 40 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: COMPANY SHARE 2021 (%)

FIGURE 41 EUROPE CANCER TREATMENT MARKET: COMPANY SHARE 2021 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The cancer treatment market size will be worth USD 524,921.84 million by 2029.
The growth rate of the cancer treatment market is 12.1%.
The major companies in the cancer treatment market are Bristol-Myers Squibb Company, F. Hoffman La-Roche Ltd, Clegen, AbbVie, Inc., Pfizer, Inc., and Novartis AG, among others.
Cancer type, treatment, route of administration, and end user are the factors on which the cancer treatment market research is based.
The high prevalence of cancer, growing geriatric cancer, and availability of advanced targeted therapies for cancer are the growth drivers of the cancer treatment market.

浏览相关页面

Banner